Salvage Therapy with Vorinostat, Lenalidomide, and Dexamethasone (ZRD) in Lenalidomide/Dexamethasone Relapsed/Refractory Multiple Myeloma

被引：9
|
作者：
Richter, Joshua R. [1 ]
Bilotti, Elizabeth [1 ]
McBride, Laura [1 ]
Schmidt, Linda [1 ]
Gao, Zhijie [2 ]
Tufail, Madiha [2 ]
Anand, Palka [1 ]
McNeill, Ann [1 ]
Bednarz, Urszula [1 ]
Graef, Thorsten [3 ]
Vesole, David H. [1 ]
Siegel, David S. [1 ]
机构：
[1] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[2] Univ Med & Dent NJ, Newark, NJ USA
[3] Merck Res Labs, Upper Gwynedd, PA USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
10.1182/blood.V118.21.3986.3986
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1706 / 1706
页数：1
相关论文
共 50 条
  • [31] Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma.
    Plesner, Torben
    Arkenau, Hendrik-Tobias
    Lokhorst, Henk M.
    Gimsing, Peter
    Krejcik, Jakub
    Lemech, Charlotte Rose
    Minnema, Monique
    Lassen, Ulrik Niels
    Ahmadi, Tahamtan
    Yeh, Howard
    Guckert, Mary
    Brun, Nikolai C.
    Lisby, Steen
    Basse, Linda
    Palumbo, Antonio
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] THE EFFICACY OF COMBINATION THERAPY WITH LENALIDOMIDE AND DEXAMETHASONE IN THE TREATMENT OF RELAPSED MULTIPLE MYELOMA
    Szudy-Szczyrek, Aneta
    Legiec, Wojciech
    Manko, Joanna
    Gmyz, Katarzyna
    Szczyrek, Michal
    Hus, Marek
    HEALTH PROBLEMS OF CIVILIZATION, 2015, 9 (02) : 50 - 54
  • [33] Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
    David S. Siegel
    Gary J. Schiller
    Christy Samaras
    Michael Sebag
    Jesus Berdeja
    Siddhartha Ganguly
    Jeffrey Matous
    Kevin Song
    Christopher S. Seet
    Giampaolo Talamo
    Mirelis Acosta-Rivera
    Michael Bar
    Donald Quick
    Bertrand Anz
    Gustavo Fonseca
    Donna Reece
    William E. Pierceall
    Weiyuan Chung
    Faiza Zafar
    Amit Agarwal
    Nizar J. Bahlis
    Leukemia, 2020, 34 : 3286 - 3297
  • [34] Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma
    Paludo, Jonas
    Mikhael, Joseph R.
    LaPlant, Betsy R.
    Halvorson, Alese E.
    Kumar, Shaji
    Gertz, Morie A.
    Hayman, Suzanne R.
    Buadi, Francis K.
    Dispenzieri, Angela
    Lust, John A.
    Kapoor, Prashant
    Leung, Nelson
    Russell, Stephen J.
    Dingli, David
    Go, Ronald S.
    Lin, Yi
    Gonsalves, Wilson I.
    Fonseca, Rafael
    Bergsagel, P. Leif
    Roy, Vivek
    Sher, Taimur
    Chanan-Khan, Asher A.
    Ailawadhi, Sikander
    Stewart, A. Keith
    Reeder, Craig B.
    Richardson, Paul G.
    Rajkumar, S. Vincent
    Lacy, Martha Q.
    BLOOD, 2017, 130 (10) : 1198 - 1204
  • [35] Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma
    Shinsuke Iida
    Takaaki Chou
    Shinichiro Okamoto
    Hirokazu Nagai
    Kiyohiko Hatake
    Hirokazu Murakami
    Toshiyuki Takagi
    Kazuyuki Shimizu
    Henry Lau
    Kenichi Takeshita
    Masaaki Takatoku
    Tomomitsu Hotta
    International Journal of Hematology, 2010, 92 : 118 - 126
  • [36] LONG TERM TREATMENT WITH LENALIDOMIDE-DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Rocchi, S.
    Petrucci, M. T.
    Zambello, R.
    Montefusco, V.
    Pantani, L.
    Gamberi, B.
    Rizzello, I.
    Nozzoli, C.
    Dozza, L.
    Borsi, E.
    De Paoli, L.
    Palmieri, S.
    Cellini, C.
    di Toritto, T. Caravita
    Tosi, P.
    Morabito, F.
    Gozzetti, A.
    Cavo, M.
    HAEMATOLOGICA, 2017, 102 : 129 - 130
  • [37] Erratum: Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma
    Nikhil C Munshi
    Constantine Mitsiades
    Paul G Richardson
    Kenneth C Anderson
    Nature Clinical Practice Oncology, 2008, 5 : 493 - 493
  • [38] Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
    Siegel, David S.
    Schiller, Gary J.
    Samaras, Christy
    Sebag, Michael
    Berdeja, Jesus
    Ganguly, Siddhartha
    Matous, Jeffrey
    Song, Kevin
    Seet, Christopher S.
    Talamo, Giampaolo
    Acosta-Rivera, Mirelis
    Bar, Michael
    Quick, Donald
    Anz, Bertrand
    Fonseca, Gustavo
    Reece, Donna
    Pierceall, William E.
    Chung, Weiyuan
    Zafar, Faiza
    Agarwal, Amit
    Bahlis, Nizar J.
    LEUKEMIA, 2020, 34 (12) : 3286 - 3297
  • [39] Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment
    Dimopoulos, M. A.
    Stewart, A. K.
    Masszi, T.
    Spicka, I.
    Oriol, A.
    Hajek, R.
    Rosinol, L.
    Siegel, D.
    Mihaylov, G. G.
    Goranova-Marinova, V.
    Rajnics, P.
    Suvorov, A.
    Niesvizky, R.
    Jakubowiak, A.
    San-Miguel, J.
    Ludwig, H.
    Ro, S.
    Aggarwal, S.
    Moreau, P.
    Palumbo, A.
    BLOOD CANCER JOURNAL, 2017, 7 : e554 - e554
  • [40] Lenalidomide plus dexamethasone demonstrates efficacy in the treatment of relapsed or refractory multiple myeloma
    不详
    FORMULARY, 2008, 43 (02) : 79 - 80
12345